ArcherDX Blog



Feb
12
2019

Press release: ArcherDX Announces Broad-Based Strategic Collaboration with Genosity

ArcherDX, Inc. today announced that it has entered into a broad strategic collaboration with Genosity Inc., a biotechnology company that provides expertise, software and technical solutions to unlock the power of precision medicine by advancing genomics and facilitating collaborative research.


Jan
30
2019

Press release: ArcherDX Acquires Baby Genes, a Genetics-Based Personalized Medicine Company

ArcherDX is pleased to announce the acquisition of Baby Genes, Inc, a privately held CLIA-certified, CAP-accredited laboratory focused on empowering individuals to take charge of their health through genetic insights.


Jan
8
2019

Press release: ArcherDX’s Companion Diagnostic Assay for both Liquid Biopsy and Tissue Specimens Granted Breakthrough Device Designation by U.S. Food and Drug Administration

ArcherDX announced that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Device designation (formerly Expedited Access Pathway program) for ArcherDx’s companion diagnostic assay application.


Dec
20
2018

How to decipher noisy regions with per-variant sensitivity detection

Background noise isn't static, so why should your sensitivity threshold be static? Traditional limit of detection measurements are based on static thresholds which average this noise, but Archer scientists have recently developed a method to model the noise at each base position requiring only a small set of samples. This method allows for position-specific sensitivity thresholds, termed 95 MDAF, which increases confidence in variant detection in noisy regions.


Nov
29
2018

Workshop: Implementing NGS to quantify human and pathogen tumor markers in plasma and tissue

Margaret Gulley, MD from the UNC School of Medicine describes her group’s method to quantify cancer mutations alongside tumor-related viral and bacterial pathogens in plasma and FFPE tissue using modified off-the-shelf Archer NGS reagents combined with Archer Analysis bioinformatics. She will discuss analytic and clinical interpretation criteria and the value of molecular barcodes and noise reduction algorithms in patient and control DNA.


Oct
18
2018

Webinar: Validation of Error-Corrected Sequencing for Hematological Malignancies

In this webinar, Drs. Catherine Rehder and Sarah Rapisardo at Duke University describes their efforts to validate the Archer® VariantPlex® Myeloid assay. They also discuss their work to expand testing with a custom Archer FusionPlex® assay to detect known and novel fusions, with a focus on Ph-like ALL fusions.


Oct
15
2018

Common tests for ROS1 translocations in lung cancer

A University of Colorado Cancer Center study published in the Journal of Thoracic Oncology highlights the limitations in common lab tests used to determine ROS1 status in lung cancer patients.


Oct
11
2018

Validation of the Archer FusionPlex Sarcoma kit

A paper published in The Journal for Molecular Diagnostics shows a direct comparison between the Archer FusionPlex Sarcoma panel and conventional methods for gene fusion detection, including fluorescence in situ hybridization (FISH) and reverse transcriptase-PCR (RT-PCR)


Oct
11
2018

Utility of Anchored Multiplex PCR for gene fusion detection®

Watch Dr. Cecilia Yeung's talk on using AMP™ technology for rapid identification of fusions in leukemias with Oxford Nanopore™ real-time sequencing from CGC 2018.


Oct
11
2018

Archer at AMP 2018

ArcherDX at the Association for Molecular Pathology annual meeting in San Antonio, TX from November 1-3, 2018

How to contact us

Address

2477 55th Street, Suite 202

Boulder, CO 80301

Phone

Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2018 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures. For Research Use Only. Not for use in diagnostic procedures.